SCHEMBL5358780

SCHEMBL5358780

CCOC(=O)c1csc2c1CCCC2=O

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
LMNA P02545 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
BRD4 O60885 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPT P10636 5/20 0.44
TP53 P04637 2/20 0.44
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 2/20 0.42
THRB P10828 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ADORA2A P29274 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14341897 0.82 SMN1; SMN2 (0.44) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL31147584 0.81 ALDH1A1 (0.37) ALDH1A1LMNASMN1; SMN2BRD4MEN1
SCHEMBL31147477 0.81 ADORA2B (0.38) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL5260554 0.81 MAPT (0.62) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL5354557 0.78 SMN1; SMN2 (0.36) ALDH1A1LMNASMN1; SMN2BRD4MEN1
SCHEMBL1007527 0.78 ALDH1A1 (0.47) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL1379362 0.78 MAPT (0.65) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL5352356 0.77 HPGD (0.49) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL1008018 0.77 MEN1 (0.41) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL5358551 0.77 L3MBTL1 (0.40) ALDH1A1LMNASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 ALDH1A1 1391/4885LMNA 4744/4885SMN1; SMN2 4036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.